Prof. OZAN YAZICI

Publication Network

Published journal articles indexed by SCI, SSCI, and AHCI

Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer: A Prospective Study

AKDOĞAN O., TÜRKMEN S., Uyar G. C., Yucel K. B., TÜFEKÇİ B., GÜRLER F., et al.

Cancers , vol.16, no.24, 2024 (SCI-Expanded)

Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

On S., KÖKSAL B., ARIK Z., Caner B., ERCAN UZUNDAL D., YAZICI O., et al.

CURRENT ONCOLOGY , vol.31, no.11, pp.6803-6813, 2024 (SCI-Expanded)

Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center

Barlas T., Sutcuoglu O., Akdogan O., Balos Toruner F. S., Akturk M. Y., Özdemir N., et al.

ENDOCRINE-RELATED CANCER , no.11, 2024 (SCI-Expanded)

Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , vol.281, no.9, pp.4991-4999, 2024 (SCI-Expanded)

The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer

Akdogan O., Ogut B., Sutcuoglu O., Sert A., Gurler F., Akyurek N., et al.

BMC CANCER , no.1, 2024 (SCI-Expanded) Sustainable Development

Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

Sekmek S., Karahan I., Ucar G., Ceylan F., Bayram D., Seven I., et al.

Clinical and Translational Oncology , vol.26, no.8, pp.1878-1885, 2024 (SCI-Expanded)

The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer

Uçar G., Sekmek S., Karahan İ., Ergün Y., Aydın İsak Ö., Tunç S., et al.

ONCOLOGY , 2024 (SCI-Expanded) Sustainable Development

The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

Yildirim H. C., Buyukkor M., KAVGACI G., Celik B. Ş., Yucel K. B., Dursun B., et al.

Medicine (United States) , vol.103, no.30, 2024 (SCI-Expanded)

A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

GÜRLER F., Tay F., Sucuoğlu İşleyen Z., Yerlikaya T., Hendem E., Esen S. A., et al.

CANCER MEDICINE , no.14, 2024 (SCI-Expanded) Sustainable Development

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC

Cho B. C., Lu S., Felip E., Spira A. I., Girard N., Lee J., et al.

NEW ENGLAND JOURNAL OF MEDICINE , 2024 (SCI-Expanded) Sustainable Development

Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas

KURT İNCİ B., Acar E., GÜRLER F., İlhan A., Yıldız F., Ardıç F., et al.

Journal of Clinical Medicine , vol.13, no.12, 2024 (SCI-Expanded)

A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., KORKMAZ T., Yumuk P. F., ÇİÇİN İ., et al.

Medicine (United States) , vol.103, no.21, 2024 (SCI-Expanded)

Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors

Yücel K. B., AYDOS U., SÜTCÜOĞLU O., Kılıç A. C., ÖZDEMİR N., ÖZET A., et al.

Cancer Chemotherapy and Pharmacology , vol.93, no.5, pp.497-507, 2024 (SCI-Expanded)

The relationship between clinical and pathological findings and FDG - PET uptake in metastatic colorectal cancers.

Kurt İnci B., Gürler F., Sütcüoğlu O., Tahtacı G., Üner A., Özet A., et al.

Indian journal of cancer , 2024 (SCI-Expanded)

Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

Gürler F., Aktürk Esen S., Kurt İnci B., Sütçüoğlu O., Uçar G., Akdoğan O., et al.

CANCER INVESTIGATION , no.2, pp.141-154, 2024 (SCI-Expanded) Sustainable Development

Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial

BİR YÜCEL K., Sutcuoglu O., YAZICI O., ÖZET A., ÖZDEMİR N.

The Lancet Gastroenterology and Hepatology , vol.9, no.2, pp.102-103, 2024 (SCI-Expanded)

Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study

BİR YÜCEL K., Uğraklı M., Sekmek S., Yıldırım N., GÜRLER F., YAZICI O., et al.

Current Medical Research and Opinion , vol.40, no.7, pp.1137-1143, 2024 (SCI-Expanded)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., Can Guven D., Yildirim H. C., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.

Integrative cancer therapies , vol.23, 2024 (SCI-Expanded)

Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy.

BİR YÜCEL K., Kilic A. C., SÜTCÜOĞLU O., YAZICI O., Kilic K., SAVAŞ G., et al.

Journal of chemotherapy (Florence, Italy) , vol.36, no.3, pp.249-257, 2024 (SCI-Expanded)

Carcinoma erysipeloides, a case-report and review of the sixty-nine cases in the literature

EROĞLU İ., ÜNER A., GÜRLER F., YAZICI O., ÖZET A., ÖZDEMİR N.

American Journal of the Medical Sciences , 2024 (SCI-Expanded)

Niraparib-induced pure red cell aplasia

BİR YÜCEL K., YILDIZ Ş., SÜTCÜOĞLU O., Güvercin F. S., UYAR GÖÇÜN F. P., ÖZDEMİR N., et al.

Journal of Oncology Pharmacy Practice , vol.30, no.1, pp.210-214, 2024 (SCI-Expanded)

Prognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine

Önder T., CENGİZ M., Koçoğlu S. S., Ateş Ö., YAZICI O., İNANÇ M., et al.

Clinical and Translational Oncology , 2024 (SCI-Expanded)

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., et al.

Expert Opinion on Pharmacotherapy , vol.25, no.11, pp.1555-1563, 2024 (SCI-Expanded)

Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy.

Kurt İnci B., Gürler F., Sütcüoğlu O., Baştuğ V., Yazıcı O., Üner A., et al.

Journal of cancer research and therapeutics , vol.19, 2023 (SCI-Expanded)

The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma

ASLAN V., KARABÖRK KILIÇ A. C., ÖZET A., ÜNER A., GÜNEL N., YAZICI O., et al.

BMC Cancer , vol.23, no.1, 2023 (SCI-Expanded)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Unal C., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.

ONCOLOGIST , vol.28, pp.875-884, 2023 (SCI-Expanded)

Combination therapies in non-clear-cell renal cell carcinoma

ASLAN V., ÖZDEMİR N., YAZICI O., ÖZET A.

The Lancet Oncology , vol.24, no.10, 2023 (SCI-Expanded)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

ULAŞ KAHYA B., ÖZDEMİR N., YAZICI O.

The New England journal of medicine , vol.389, no.5, pp.476, 2023 (SCI-Expanded)

Correspondence: Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

AKDOĞAN O., SÜTCÜOĞLU O., ÖZET A., YAZICI O., ÖZDEMİR N.

Supportive Care in Cancer , vol.31, no.8, 2023 (SCI-Expanded)

Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer

Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., Güven D. C., Kavuncuoğlu A., ÖZDEMİR N., et al.

Strahlentherapie und Onkologie , vol.199, no.8, pp.761-772, 2023 (SCI-Expanded)

Evaluation of scientific reliability and quality of YouTube videos on cancer and nutrition

Sutcuogolu O., Ozay Z. I., ÖZET A., YAZICI O., Ozdemeir N.

NUTRITION , vol.108, 2023 (SCI-Expanded) Sustainable Development

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade

ASLAN V., YAZICI O., ÖZDEMİR N.

JAMA ONCOLOGY , vol.9, pp.570-0, 2023 (SCI-Expanded)

Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment

BİR YÜCEL K., SÜTCÜOĞLU O., YAZICI O., YILDIZ Y., ŞENOL E., ÜNER A.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3, pp.760-763, 2023 (SCI-Expanded)

Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

SÜTCÜOĞLU O., Doğan A., Yilmaz F., Şahin A. B., Şahin T. K., Esen S. A., et al.

Pancreas , vol.52, no.4, 2023 (SCI-Expanded)

Greater financial toxicity correlates with increased psychological distress and lower quality of life among Turkish cancer patients

Yücel K. B., Özay Z. I., SÜTCÜOĞLU O., YAZICI O., ÜNER A., GÜNEL N., et al.

Supportive Care in Cancer , vol.31, no.2, 2023 (SCI-Expanded) Sustainable Development

Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?

SÜTCÜOĞLU O., Rustamova Cennet N., ÖZET A., ÖZDEMİR N., YAZICI O.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.41, no.2, pp.416-417, 2023 (SCI-Expanded)

Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Almuradova E., Basoglu T., Nayir E., Bayram E., PAYDAŞ S., Gokmen I., et al.

NEOPLASMA , vol.70, no.1, pp.158-165, 2023 (SCI-Expanded)

The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective

SÜTCÜOĞLU O., ERDAL Z. S., Akdoğan O., ÇELTİKÇİ E., ÖZDEMİR N., ÖZET A., et al.

Turkish Journal of Medical Sciences , vol.53, no.1, pp.420-431, 2023 (SCI-Expanded)

Major and minor salivary gland cancers: A multicenter retrospective study

Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.

Head and Neck , vol.45, 2023 (SCI-Expanded) Sustainable Development

Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm?

Sütcüoğlu O., Özet A., Yazıcı O., Özdemir N.

Journal of Clinical Oncology , vol.40, no.34, pp.4027, 2022 (SCI-Expanded)

Renal Clear Cell Carcinoma with Unknown Primary: Is It Real Entity or Just Hypothesis?

BÖRÜ Y. E., SÜTCÜOĞLU O., ÇALIŞKAN GÜNEŞ K., UYAR GÖÇÜN F. P., YAZICI O.

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , vol.32, pp.200-202, 2022 (SCI-Expanded) Sustainable Development

Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors

Acar E., ESENDAĞLI G., YAZICI O., DURSUN A.

Clinical Breast Cancer , vol.22, no.8, 2022 (SCI-Expanded)

Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma

Aslan V., Kılıç A. C., Sütcüoğlu O., Eraslan E., Bayrak A., Öksüzoğlu B., et al.

Urologic Oncology: Seminars and Original Investigations , vol.40, no.11, 2022 (SCI-Expanded) Sustainable Development

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

Ulaş Kahya B., Sütcüoğlu O., Yazıcı O., Özdemir N.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.33, 2022 (SCI-Expanded)

Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer

AKDOĞAN O., Sutcuoglu O., Ogut B., Akyurek N., Ozdemir N., Ozet A., et al.

IMMUNOTHERAPY , vol.14, no.14, pp.1121-1131, 2022 (SCI-Expanded) Sustainable Development

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

SÜTCÜOĞLU O., ÖZET A., YAZICI O., ÖZDEMİR N.

LANCET ONCOLOGY , vol.23, no.10, 2022 (SCI-Expanded)

Current status of biosimilars in Turkey: A survey among medical oncologists

Gürler F., Kasım D. D., Kurt İnci B., Sütçüoğlu O., Ünsal O., Aslan V., et al.

Journal of Oncology Pharmacy Practice , vol.28, no.7, pp.1516-1523, 2022 (SCI-Expanded)

Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer

ASLAN V., SÜTCÜOĞLU O., ÖZET A., ÖZDEMİR N., YAZICI O.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.19, pp.2177-2179, 2022 (SCI-Expanded)

How molecularly similar are primary and metastatic tissues in renal cell carcinoma?

Ulaş Kahya B., Sütcüoğlu O., Özdemir N., Yazıcı O.

LANCET ONCOLOGY , vol.23, no.7, 2022 (SCI-Expanded)

Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis

ÜNSAL O., SÜTCÜOĞLU O., YAZICI O.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, pp.486-488, 2022 (SCI-Expanded)

ROAR trial: which treatment is effective after progression?

SÜTCÜOĞLU O., Yücel K., ÜNER A., YAZICI O., ÖZDEMİR N.

LANCET ONCOLOGY , vol.23, no.3, 2022 (SCI-Expanded)

A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma

DEMİR E., SÜTCÜOĞLU O., DEMİR B., ÜNSAL O., YAZICI O.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, pp.445-448, 2022 (SCI-Expanded) Sustainable Development

Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?

Sütcüoğlu O., Ulaş Kahya B., Özdemir N., Yazıcı O.

Journal Of Clinical Oncology , vol.0, no.0, pp.12-13, 2022 (SCI-Expanded) Sustainable Development

Bone marrow involvement in breast cancer

SÜTCÜOĞLU O., ÖZDEMİR N., YAZICI O., ÖZET A.

CURRENT PROBLEMS IN CANCER , vol.46, no.1, 2022 (SCI-Expanded) Sustainable Development

Clinical and laboratory outcomes of the solid cancer patients reinfected with SARS-CoV-2

ÜNSAL O., YAZICI O., ÖZDEMİR N., ÇUBUKÇU E., OCAK B., ÜNER A., et al.

FUTURE ONCOLOGY , vol.18, no.5, pp.533-541, 2022 (SCI-Expanded) Sustainable Development

Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

Gürler F., İlhan A., Güven D. C., Turhan O., Kurt İnci B., Sütçüoğlu O., et al.

Anti-Cancer Drugs , vol.33, no.1, pp.477-485, 2022 (SCI-Expanded) Sustainable Development

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gürler F., Güven D. C., Aydemir E., Sütcüoğlu O., Kurt İnci B., Arık Z., et al.

Turkish Journal of Medical Sciences , vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded)

Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome

YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S., Yildiz B., Karamouzis M., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.38, no.4, pp.579-586, 2022 (SCI-Expanded) Sustainable Development

Effects of Sarcopenia, Myosteatosis, and the Prognostic Nutritional Index on Survival in Stage 2 and 3 Gastric Cancer Patients

BİR YÜCEL K., Kilic A. C., SÜTCÜOĞLU O., YAZICI O., AYDOS U., Kilic K., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , vol.75, pp.368-375, 2022 (SCI-Expanded) Sustainable Development

Thirty-day mortality rates after immunotherapy initiation.

Sütcüoğlu O., İlhan A., Tacar S. Y., Güven D. C., Uçar G., Karadurmuş N., et al.

Immunotherapy , vol.13, pp.1419-1426, 2021 (SCI-Expanded)

Is it necessary to measure basal serum lipid levels in cancer patients prior to tamoxifen treatment?

Sütcüoğlu O., Yazıcı O., Özet A.

Future oncology (London, England) , vol.17, pp.4823-4825, 2021 (SCI-Expanded)

Brigatinib-induced tuberculosis reactivation: A case report

KEŞ V., SÜTCÜOĞLU O., GÜRLER F., YAZICI O., ÖZET A.

Current Problems in Cancer , vol.45, 2021 (SCI-Expanded) Sustainable Development

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., Eren T., Zeynelgil E., Imamoglu G. I., Altinbas M., Karadag I., et al.

FUTURE ONCOLOGY , vol.17, no.33, pp.4447-4456, 2021 (SCI-Expanded) Sustainable Development

Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

SÜTCÜOĞLU O., ÖZDEMİR N., YAZICI O.

EUROPEAN JOURNAL OF CANCER , vol.155, pp.294-295, 2021 (SCI-Expanded)

The role of serum albumin/globulin ratio in combination with prognostic risk indexes of febrile neutropenia

SÜTCÜOĞLU O., AKDOĞAN O., GÜRLER F., KURT İNCİ B., ÖZDEMİR N., ÖZET A., et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.75, no.7, 2021 (SCI-Expanded) Sustainable Development

Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data

ÖZDEMİR N., DİZDAR Ö., YAZICI O., AKSOY S., Dede D. S., Budakoglu B., et al.

INTERNATIONAL JOURNAL OF CANCER , vol.148, no.10, pp.2407-2415, 2021 (SCI-Expanded) Sustainable Development

A detailed in-silico analysis of potential gastric cancer molecular marker genes in the literature

AKTAŞ S. H., Akin-Bali D. F., YAZICI O.

International Journal of Data Mining and Bioinformatics , vol.25, no.3-4, pp.201-215, 2021 (SCI-Expanded) Sustainable Development

Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer

YAZICI O., Dogan M., Ozal G., AKTAŞ S. H., Demirkazik A., Utkan G., et al.

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING , vol.24, no.8, pp.1229-1235, 2021 (SCI-Expanded) Sustainable Development

Harmful consequences of COVID-19 fear in patients with cancer.

Sutcuoglu O., Yazici O., Ozet A., Ozdemir N.

BMJ supportive & palliative care , 2020 (SCI-Expanded) Sustainable Development

Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients

Eren T., Karacin C., Ucar G., Ergun Y., YAZICI O., Imamoglu G. I., et al.

MEDICINE , vol.99, no.22, 2020 (SCI-Expanded) Sustainable Development

Efficacy of the Combination of Modified Docetaxel, Cisplatin and Fluorouracil in Locally Advanced Gastric Cancer: Evaluation of Real-Life Outcomes

Eren T., Karacin C., Ucar G., Ergun Y., YAZICI O., Imamoglu G. I., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.30, no.1, pp.23-31, 2020 (SCI-Expanded) Sustainable Development

Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer

Bozkaya Y., YAZICI O.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.3, pp.267-272, 2019 (SCI-Expanded) Sustainable Development

Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

YILDIZ İ., Bilici A., Karadurmus N., OZER L., Tural D., Kaplan M. A., et al.

TUMORI JOURNAL , vol.104, no.6, pp.444-450, 2018 (SCI-Expanded)

Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer

Bozkaya Y., Ozdemir N., Erdem G. U., Demirci N. S., Yazici O., Hocazade C., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.14, no.6, pp.1330-1335, 2018 (SCI-Expanded) Sustainable Development

Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen

Bozkaya Y., Erdem G. U., Ozdemir N. Y., Hocazade C., Yazici O., Demirci N. S., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.14, 2018 (SCI-Expanded)

Global cancer control: responding to the growing burden, rising costs and inequalities in access

Prager G. W., Braga S., Bystricky B., Qvortrup C., Criscitiello C., Esin E., et al.

ESMO OPEN , vol.3, no.2, 2018 (SCI-Expanded) Sustainable Development

5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane

Erdem G. U., Bozkaya Y., Ozdemir N. Y., Demirci N. S., Yazici O., Zengin N.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , vol.18, no.2, pp.170-177, 2018 (SCI-Expanded)

Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?

Bozkaya Y., Ozdemir N. Y., Sezer S., Kostek O., Demirci N. S., Yazici O., et al.

CANCER BIOMARKERS , vol.22, no.1, pp.143-149, 2018 (SCI-Expanded) Sustainable Development

The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma

Bozkaya Y., Dogan M., Yazici O., Erdem G. U., Demirci N. S., Zengin N.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , vol.17, no.2, pp.138-143, 2017 (SCI-Expanded) Sustainable Development

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Aktas S. H., AKBULUT H., Yazici O., Zengin N., Akgun H. N., Ustuner Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2, pp.399-406, 2017 (SCI-Expanded) Sustainable Development

Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Bilir C., Yildiz I., Bilici A., Ucar M., Berk V., Yildiz Y., et al.

CANCER INVESTIGATION , vol.35, no.4, pp.248-255, 2017 (SCI-Expanded)

Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer

Bozkaya Y., Dogan M., Erdem G. U., Tulunay G., Uncu H., Arik Z., et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY , vol.37, no.5, pp.649-654, 2017 (SCI-Expanded) Sustainable Development

Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Bozkaya Y., Erdem G. U., Ozdemir N. Y., Demirci N. S., Hocazade C., Yazici O., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.33, no.1, pp.109-116, 2017 (SCI-Expanded)

The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer

Yazilitas D., Ozdemir N., Yazici O., Hocazade C., Demirci N. S., Zengin N.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.12, no.4, pp.1257-1260, 2016 (SCI-Expanded) Sustainable Development

Inflammation and chemerin in colorectal cancer

Erdogan S., YILMAZ F. M., Yazici O., Yozgat A., Sezer S., Ozdemir N., et al.

TUMOR BIOLOGY , vol.37, no.5, pp.6337-6342, 2016 (SCI-Expanded) Sustainable Development

Targeted therapies in gastric cancer and future perspectives

Yazici O., ŞENDUR M. A. N., Ozdemir N., AKSOY S.

WORLD JOURNAL OF GASTROENTEROLOGY , vol.22, no.2, pp.471-489, 2016 (SCI-Expanded) Sustainable Development

Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.

Sendur M. A. N., Aksoy S., Ozdemir N. Y., Zengin N., Yazici O., Sever A. R., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.21, no.1, pp.27-34, 2016 (SCI-Expanded) Sustainable Development

Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)

Kaplan M. A., Arslan U. Y., Isikdogan A., Dane F., Oksuzoglu B., İNANÇ M., et al.

BREAST CARE , vol.11, no.4, pp.248-252, 2016 (SCI-Expanded) Sustainable Development

The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO

Yazici O., Ozdemir N., Duran A. O., Menekse S., Ali M., Sendur N., et al.

FUTURE ONCOLOGY , vol.12, no.3, pp.343-354, 2016 (SCI-Expanded) Sustainable Development

A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience.

Yazilitas D., Ozdemir N., Hocazade C., Bozkaya Y., Yazici O., Sendur M. A. N., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, no.6, pp.1526-33, 2015 (SCI-Expanded)

Squamous cell and neuroendocrine carcinoma of esophagus: Collision versus composite tumor: A case report and review of literature

Yazici O., Aksoy S., Ozhamam E. U., Zengin N.

INDIAN JOURNAL OF CANCER , vol.52, no.4, pp.603-604, 2015 (SCI-Expanded)

Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer

Hocazade C., Ozdemir N., Yazici O., Bozkaya Y., Yazilitas D., Toptas S., et al.

ANNALS OF NUCLEAR MEDICINE , vol.29, no.7, pp.621-626, 2015 (SCI-Expanded) Sustainable Development

The effect of obesity on recurrence pattern in early breast cancer patients.

Yazici O., Aksoy S., Sendur M. A., Babacan T., Ozdemir N., Ozisik Y., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, no.4, pp.954-62, 2015 (SCI-Expanded) Sustainable Development

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma

Erdem G. U., Sendur M. A. N., Ozdemir N. Y., Yazici O., Zengin N.

CURRENT MEDICAL RESEARCH AND OPINION , vol.31, no.4, pp.743-756, 2015 (SCI-Expanded)

Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer

Sendur M. A. N., AKSOY S., YORGUN H., Ozdemir N., Yilmaz F. M., Yazici O., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.31, no.3, pp.547-556, 2015 (SCI-Expanded) Sustainable Development

Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma

GÜLTEKİN M., Yazici O., Eren G., YÜCE D., AKSOY S., Ozisik Y., et al.

BREAST , vol.23, no.6, pp.775-783, 2014 (SCI-Expanded)

The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., Zengin N., Altundag K.

CURRENT MEDICAL RESEARCH AND OPINION , vol.30, no.12, pp.2535-2542, 2014 (SCI-Expanded) Sustainable Development

Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma.

Civelek B., Aksoy S., Sendur M. A. N., Yazici O., Kanmaz H., Kos F. T., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.19, no.4, pp.906-12, 2014 (SCI-Expanded)

Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

ŞENDUR M. A. N., Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinci A. S., et al.

MEDICAL ONCOLOGY , vol.31, no.9, 2014 (SCI-Expanded) Sustainable Development

Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.

Yildiz I., Ekenel M., Akman T., Kocar M., Uysal M., Kanitez M., et al.

Anticancer research , vol.34, no.8, pp.4329-34, 2014 (SCI-Expanded)

Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma

Yazici O., Ozdemir N. Y., Sendur M. A. N., AKSOY S., Zengin N.

CURRENT MEDICAL RESEARCH AND OPINION , vol.30, no.7, pp.1327-1336, 2014 (SCI-Expanded)

Hepatitis C virus reactivation in cancer patients in the era of targeted therapies

Yazici O., Sendur M. A. N., AKSOY S.

WORLD JOURNAL OF GASTROENTEROLOGY , vol.20, no.22, pp.6716-6724, 2014 (SCI-Expanded) Sustainable Development

Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer

Sendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., Zengin N., Altundag K.

MEDICAL ONCOLOGY , vol.31, no.2, 2014 (SCI-Expanded) Sustainable Development

Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded)

Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients

Turker I., Arslan U. Y., Yazici O., Uyeturk U., Oksuzoglu B., Budakoglu B., et al.

BREAST CARE , vol.9, no.6, pp.421-427, 2014 (SCI-Expanded) Sustainable Development

Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

Gumusay O., Coskun U., Akman T., Ekinci A. S., Kocar M., Erceleb O. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.140, no.1, pp.151-157, 2014 (SCI-Expanded)

Evaluation of erectile dysfunction risk factors in young male survivors of colorectal cancer.

Sendur M. A. N., Aksoy S., Ozdemir N. Y., Yaman S., Yazici O., Bulent Akinci M., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.19, no.1, pp.115-23, 2014 (SCI-Expanded) Sustainable Development

Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"

Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., et al.

WIENER KLINISCHE WOCHENSCHRIFT , vol.126, no.1-2, pp.36-41, 2014 (SCI-Expanded) Sustainable Development

Arrhythmias during and after zoledronic acid infusion patients with bone metastasis

Yazici O., AKSOY S., Ucar O., Ozdemir N., DEMİR M., Sendur M. A. N., et al.

MEDICAL ONCOLOGY , vol.30, no.3, 2013 (SCI-Expanded) Sustainable Development

Tuberculosis of the breast in a patient undergoing hemodialysis

Yazici O., Mescigil P., Kepenekci I., Celepli P., ŞENGÜL Ş., AZAP A., et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY , vol.43, no.1, pp.241-244, 2011 (SCI-Expanded) Sustainable Development

Articles Published in Other Journals

Evaluation of Volumetric Magnetic Resonance Imaging in Determining the Indication for Total Neoadjuvant Therapy in Rectal Cancer

SÜTCÜOĞLU O., Leyla S., BİR YÜCEL K., ÖZET A., İNAN M. A., YAZICI O., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.56, no.1, 2025 (ESCI)

Olfactory Effects of Chemotherapy Combined with Bevacizumab on Advanced-Stage Colorectal Cancer Patients: Chemotherapy and Olfaction

Uzunoğlu E., CEYLAN A., Eravcı F. C., ŞAHİN M. M., CEBECİ S., YAZICI O., et al.

Indian Journal of Otolaryngology and Head and Neck Surgery , 2025 (ESCI)

Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline

BİR YÜCEL K., Sutcuoglu O., YAZICI O., ÖZET A., ÖZDEMİR N.

Memo - Magazine of European Medical Oncology , vol.17, no.4, pp.302-306, 2024 (ESCI)

Unusual presentation of melena due to duodenal metastasis from primary lung adenocarcinoma

Bilican G., Dumanlı S., Yıldırım E., Karataş A., Sert A., Yazıcı O.

Current Problems in Cancer: Case Reports , vol.16, 2024 (Scopus)

Adjuvant Temozolomide Therapy Tolerance in Geriatric Glioblastoma Multiforme Patients

KURT İNCİ B., KARADAĞ İ., İŞBİLİR G. D., Tomar V. B., GÜRLER F., KUBİLAY TOLUNAY P., et al.

European Journal of Geriatrics and Gerontology , vol.6, no.3, pp.165-170, 2024 (Peer-Reviewed Journal)

Retrospective Evaluation of the Efficacy and Safety of Niraparib Maintenance; Real World Data on Turkish Early-Access Program

BİR YÜCEL K., TOPAL A., YAZICI O., KARADURMUŞ N., UYSAL M., ÖZDEMİR N., et al.

Eurasian Journal of Medical Investigation , vol.8, no.3, pp.205-211, 2024 (Peer-Reviewed Journal)

The Prognostic Value of the Preoperative Geriatric Nutritional Risk Index in Elderly Colon Cancer Patients Underwent Curative Resection

Bir Yücel K., sutcuoglu o., Uğur T., Çağdaşer Ç., YAZICI O., Ozdemir N., et al.

ACTA ONCOLOGICA TURCICA , vol.57, no.1, pp.14-21, 2024 (Peer-Reviewed Journal)

The Reallife Comparison of FOLFIRINOX vs Gemcitabine Platinum Combination as a First-Line Treatment in Patients with Pancreatic Carcinoma

Kurt İnci B., Gürler F., Sütcüoğlu O., Ünsal O., Aslan V., Yazıcı O., et al.

Journal of oncological sciences , vol.10, no.1, pp.32-38, 2024 (Scopus)

Retrospective Analysis of Real-Life Data Evaluating the Optimal Time Between Gastrectomy and Adjuvant Chemotherapy in Resected Gastric Cancer

Yücel K. B., SÜTCÜOĞLU O., YAZICI O., ÖZET A., ÖZDEMİR N.

Journal of Gastrointestinal Cancer , vol.54, no.4, pp.1268-1275, 2023 (ESCI) Sustainable Development

Earthquake disaster impact on health care of cancer patients: Single-centre experience

Ünsal O., Yazıcı O., Özdemir N., Savaş G., Özet A.

TURKISH JOURNAL OF INTERNAL MEDICINE , vol.5, no.4, pp.234-239, 2023 (Peer-Reviewed Journal)

Long-term outcomes of COVID-19 infection in patients with solid tumors

Ünsal O., YAZICI O., özkan ö. f., tahtaci g., Ozdemir N., Üner A., et al.

The European Research Journal , vol.9, no.5, pp.932-939, 2023 (Peer-Reviewed Journal)

COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors

ÜNSAL O., YAZICI O., ÖZDEMİR N., SAVAŞ G., ÖZET A.

Eurasian Journal of Medical Investigation , vol.7, no.4, pp.419-425, 2023 (Peer-Reviewed Journal)

Real-World Outcomes of Second-Line Treatment in Sensitive Relapsed Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Gürler F., İlhan Güleşen A., Taban H., Yılmaz F., Şeyran E., Dursun E., et al.

Eurasian Journal of Medical Investigation , vol.7, no.3, pp.321-328, 2023 (Peer-Reviewed Journal)

Prognostic Significance of the Gustave-Roussy Immune Score in Colon Cancer Patients Treated with Adjuvant CAPEOX Regimen

BİR YÜCEL K., SÜTCÜOĞLU O., UĞUR TUZCU T., ÇAĞDAŞER Ç., YAZICI O., ÖZET A., et al.

Eurasian Journal of Medical Investigation , 2023 (Peer-Reviewed Journal)

Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Ünsal O., Yazıcı O., Ozdemir N., Ozet A.

Annals of Medical Research , vol.30, no.8, pp.965-969, 2023 (Peer-Reviewed Journal)

Tam Kan Sayımı Parametreleri ile İleri Evre Mide Kanseri Olan Hastaların Prognozunu Tahmin Edilebilir Mi?

Sütcüoğlu O., Fincan A., Gürler F., İnci B. K., Özdemir N., Yazıcı O.

Turkish Journal of Clinics and Laboratory , vol.14, no.2, pp.243-245, 2023 (Peer-Reviewed Journal)

Krukenberg Tumor Presentation of Recurrent Gallbladder Cancer After a Decade

Tuzcu B., SÜTCÜOĞLU O., KOLAY BAYRAM E., Erdem O., YAZICI O.

JOURNAL OF GASTROINTESTINAL CANCER , vol.54, no.1, pp.264-267, 2023 (ESCI) Sustainable Development

Oxidized Regenerated Cellulose can be a Cause of False Tumor Recurrence on PET/CT in Patients with Lung Cancer Treated Surgically Cerrahi Olarak Tedavi Edilen Akciğer Kanserlerinde Okside Rejenere Selüloz, PET/BT’de Yalancı Tümör Nüksünün Bir Sebebi Olabilir

SAYAN M., ÇELİK A., Türk M. Ş., Özkan D., AKARSU I., YAZICI O., et al.

Molecular Imaging and Radionuclide Therapy , vol.32, no.1, pp.8-12, 2023 (Scopus)

Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

YILMAZ M., BAŞAK M., TATAROĞLU ÖZYÜKSELER D., YILDIRIM M. E., ARIK Z., SALMAN M. C., et al.

TURK ONKOLOJI DERGISI , vol.38, no.3, pp.323-332, 2023 (ESCI)

Solid Tumors other than Breast Cancer are Associated with Germ-lineATMHeterozygosity

ÜNSAL O., YAZICI O., ÖZDEMİR N., Güvercin B., ÖZET A., ERGÜN M. A.

GAZI MEDICAL JOURNAL , vol.34, pp.432-435, 2023 (ESCI)

Association of Immunoscore, CD73 Expression and 53BP1 Expression with Neoadjuvant Chemoradiotherapy Efficacy in Patients with Locally Advanced Rectal Cancer

Sütcüoğlu O., İnan M. A., Üner A., Savaş G., Bora H., Özet A., et al.

Journal of oncological sciences , vol.9, no.1, pp.23-32, 2023 (Scopus)

A Case of Burned-out Testicular Germ Cell Tumor Diagnosed Eleven Years Later On Bir Yıl Sonra Teşhis Edilen Spontan Regrese Olmuş Testis Germ Hücreli Tümör Olgusu

AYDEMİR E., SÜTCÜOĞLU O., Gönül İ. I., ONARAN M., YAZICI O.

Gazi Medical Journal , vol.34, no.4, pp.443-445, 2023 (ESCI)

Prognostic Importance of the Lymph Node Ratio in Stage III Colorectal Cancers

ERDOĞAN K., Yılmaz N., Erdoğan A., SÜTCÜOĞLU O., YAZICI O., ÖZDEMİR N.

Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi , vol.29, pp.661-670, 2022 (Peer-Reviewed Journal)

Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options

Hazır B., Şimşek B., Erdemir A., Gürler F., Yazıcı O., Kızıl Y., et al.

HEAD & NECK PATHOLOGY , vol.16, no.2, pp.596-601, 2022 (ESCI)

Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Ergün Y., Uçar G., Aktürk Esen S., Bardakçi M., Kalkan Z., Urakçi Z., et al.

Journal of Oncological Science , vol.8, no.2, pp.100-106, 2022 (Scopus)

Review of Immunotherapy Efficacy in Virus-associated Cancers

Ozay Z. I., SÜTCÜOĞLU O., ÖZDEMİR N., YAZICI O.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.6, no.2, pp.100-110, 2022 (ESCI) Sustainable Development

Survivin As an Immunohistochemical Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis

AKTAŞ S. H., Emir B., Akin Bali D. F., YAZICI O.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, pp.129-138, 2022 (ESCI)

Prognostic and Predictive Value of NAR Score in Gastric Cancer

Ucar G., Acikgoz Y., Ergun Y., Eren T., Dirikoc M., Esen S. A., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.52, no.3, pp.1054-1060, 2021 (ESCI) Sustainable Development

Neoadjuvan Kemoterapi Alan Lokal İleri Mide Kanserli Hastalarda Primer Tümör Lokalizasyonunun Önemi

UÇAR G., EREN T., ERGÜN Y., YAZICI O., UNCU D., ÖZDEMİR M., et al.

Dicle Tıp Dergisi , vol.47, no.4, pp.962-969, 2020 (Peer-Reviewed Journal) Sustainable Development

HER2-pozitif lokal ileri meme kanserinde neoadjuvan trastuzumab sıralamasının patolojik tam yanıt üzerine etkisi

ERGÜN Y., ÖZDEMİR N., YAZICI O., UÇAR G., AÇIKGÖZ Y., BAL Ö., et al.

Bozok Tıp Dergisi , vol.10, no.2, pp.47-54, 2020 (Peer-Reviewed Journal) Sustainable Development

Local treatment options for management of loco-regional esophageal squamous cell carcinoma

EREN T., İMAMOĞLU İ., YILDIZ F., ARSLAN S., KOCACAN S., ÇAKAR S., et al.

Romanian Journal of Military Medicine , vol.122, pp.36-42, 2019 (ESCI) Sustainable Development

Comparison of definitive chemoradiotherapy and surgical results in local advanced (stage iiia and iiib) non-small cell lung cancer: single-center experience

YILMAZ M., YÜCEL B., KİRMAN D., AKDOĞAN O., YAZICI O.

Cumhuriyet Medical Journal , 2019 (Scopus) Sustainable Development

Clinical predictive factors associated with pathologic complete response in locally advanced rectal cancer

bozkaya y., ÖZDEMİR N., erdem g. u., karcı e., ÜRÜN Y., demirci n. s., et al.

Journal of Oncological Sciences , vol.4, no.1, pp.5-10, 2018 (Peer-Reviewed Journal) Sustainable Development

Panitumumab İlişkili Trikomegali: Olgu Sunumu

Ergün Y., doğan m., bal ö., YAZICI O., uçar g., ZENGİN N.

Acta Oncologica Turcica , vol.51, no.1, pp.91-93, 2018 (Peer-Reviewed Journal)

MemeKanserindeEpidemiyolojikVeriler,RiskFaktörleri,RiskAzaltıcıYaklaşımlar

YAZICI O., ÖZDEMİR N.

Türkiye Klinikleri , 2018 (Peer-Reviewed Journal)

A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer

bozkaya y., ÖZDEMİR N., YAZICI O., demirci n. s., kurtipek a., erdem g. u., et al.

Asian Pacific Journal Of Cancer Prevention , vol.19, no.1, pp.283-290, 2018 (Scopus) Sustainable Development

Gastric Cancer Patients with Bone Marrow Metastasis: A Single-Center Experience and Review of the Literature

ERGÜN Y., UNCU D., YAZICI O., UÇAR G., KARABUĞA E. K., ZENGİN N.

Eurasian Journal of Medicine and Oncology , vol.1, no.3, pp.160-163, 2017 (ESCI) Sustainable Development

The clinicopathological characteristies of the patients with solidpseudopapillary tumor of the pancreas

ÖZDEMİR N., bozkaya y., doğan m., algın e., YAZICI O., balcı ö., et al.

Acta Oncologica Turcica , 2017 (Peer-Reviewed Journal)

Alteration of thyroid functions in patients with renalcell carcinoma treated with tyrosine kinaseinhibitors Turkish population study

BİLİR C., YILDIZ İ., BİLİCİ A., UÇAR M., BERK V., YILDIZ Y., et al.

Journal of Human Rhythm , vol.2, no.4, pp.144-148, 2016 (Peer-Reviewed Journal)

Squamous Cell Cancer of The Lung with Synchronous Renal Cell Carcinoma

Ates I., Yazici O., Ates H., Yazilitas D., Ozcan A. N., Agackiran Y., et al.

TURKISH THORACIC JOURNAL , vol.17, no.3, pp.125-127, 2016 (ESCI) Sustainable Development

Helicobacter Pylori Seropostivity of Colon Cancer

Köş T. F., Sezer S., YAZICI O., Civelek B., Yıldız A., AKSOY S., et al.

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE , vol.6, no.1, pp.79-82, 2015 (Peer-Reviewed Journal) Sustainable Development

Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin cyclophosphamide followed by paclitaxel or docetaxel in patients with node positive breast cancer

Yazilitas D., ŞENDUR M. A. N., KARACA H., ÖZDEMİR N., AKSOY S., BERK V., et al.

Asian Pacific journal of cancer prevention : APJCP , vol.16, no.4, pp.1471-7, 2015 (Peer-Reviewed Journal) Sustainable Development

Kanserde Metabolik Bozukluklar ve Kardiyovasküler Hastalıklar

YAZICI O., ŞENDUR M. A. N.

Türk Kardiyoloji Seminerleri , no.2, pp.98-110, 2014 (Non Peer-Reviewed Journal) Sustainable Development

Nadir görülen sarkom türleri

Yazılıtaş D., YAZICI O., Demirci N. S.

Turkiye Klinikleri Tıbbi Onkoloji Yumuşak Doku Tümörleri Özel Sayısı , vol.7, no.1, pp.61-66, 2014 (Peer-Reviewed Journal)

Yumuşak doku sarkomlarında adjuvan kemoterapi

Yazılıtaş D., YAZICI O., Demirci N. S.

Turkiye Klinikleri Tıbbi Onkoloji Yumuşak Doku Tümörleri Özel Sayısı , vol.7, no.1, pp.23-26, 2014 (Peer-Reviewed Journal)

A rare coincidence facioscapulohumeral muscular dystrophy and breast cancer

YAZICI O., AKSOY S., ÖZDEMİR N., ŞENDUR M. A. N., Doğan M., ZENGİN N.

EXPERIMENTAL ONCOLOGY , vol.35, no.4, pp.311-312, 2013 (Scopus) Sustainable Development

Primer Santral Sinir Sistemi Tümörleri İçin Gelecekte Klinik Kullanıma Girmesi Beklenen Tedavi Şekilleri ve Ajanları

YAZICI O., Dogan M.

Türkiye Klinikleri Tıbbi Onkoloji Santral Sinir Sitemi Tümörleri Özel Sayısı , vol.6, no.1, pp.78-82, 2013 (Peer-Reviewed Journal)

The Benefit of chemotherapy in a patient with gastric medullary cancer

ŞEKER M. M., YAZICI O., Turhan N., AKSOY S., Kacan T., Babacan N., et al.

Acta Medica , vol.2, pp.45-47, 2013 (Peer-Reviewed Journal) Sustainable Development

Unusual Metastatic Site For Nasopharynx Carcinoma A Case Report

YAZICI O., Dogan M., Ucaryilmaz E., ZENGİN N.

Acta Oncologica Turcica , vol.46, no.1, pp.46-49, 2013 (Peer-Reviewed Journal)

Clinical features and prognostic factors of hepatocellular carcinoma patients single center experience

Alanlı R., Köş F. T., Uncu D., YAZICI O., ÖZDEMİR N., AKSOY S., et al.

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.28, no.4, pp.143-149, 2013 (Scopus)

Hepatosellüler kanserli hastaların klinik özellikleri ve prognostik faktörleri: tek merkez deneyimi

ALANLI R., Kos F. T., UNCU D., YAZICI O., ÖZDEMİR N., AKSOY S., et al.

Türk Onkoloji Dergisi , vol.28, pp.143-149, 2013 (Scopus) Sustainable Development

Hepatosellülr Karsinomda Yeni Tanı ve Tedavi Yöntemleri

Seven G., Özbek N., Öztürk S., Süleymanov Z., YAZICI O., Özden A.

Güncel Gastroenteroloji , vol.12, no.1, pp.47-52, 2008 (Peer-Reviewed Journal)

Poems Sendromu

Seven G., Özbek N., Öztürk S., Süleymanov Z., YAZICI O., Özden A.

Güncel Gastroenteroloji , vol.12, no.1, pp.47-52, 2008 (Peer-Reviewed Journal)

Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study

Ilhan A., Gurler F., Yilmaz F., Seyran E., Baştuğ V., Gorgulu B., et al.

CUREUS JOURNAL OF MEDICAL SCIENCE , vol.15, no.3, 1 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancer

ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., YAZICI O., AKINCI M. B., ŞENER DEDE D., et al.

41st ESMO Congress (ESMO 2016), 7 - 11 October 2016 Sustainable Development

VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)

Sadiq A. A., Shamai S., Lin S., Han J., Baijal S., Yazici O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024

Can artificial intelligence provide accurate and reliable answers to cancer patients questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain

BİR YÜCEL K., YAZICI O., ÖZDEMİR N., ÖZET A.

ESMO 2023, Madrid, Spain, 20 October 2023, vol.34, pp.1124

Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer

KARAÇİN C., ASLAN F., DUMLUDAĞ A., ALKAN A., TÜRKER M., BİR YÜCEL K., et al.

ESMO 2023, Madrid, Spain, 20 - 24 October 2023, vol.34, pp.368

Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis

ÇETİN T. E., SÜTCÜOĞLU O., ÜNER A., GÜNEL N., SAVAŞ G., ÖZDEMİR N., et al.

ESMO Congress 2023, Madrid, Spain, 20 - 24 October 2023

Kolorektal Kanserli Hastalarda Kemoterapinin Fekal Mikrobiyota Üzerine Etkisinin Metagenomik Analizi

AKTAŞ S. H., YAZICI O., DEMİR L., ELDEM V., NURAL YAMAN B., AYTAR ÇELİK P., et al.

Uluslararası Katılımlı 22. Biyoteknoloji Kongresi, Ankara, Turkey, 20 - 22 October 2023

Evaluation of the quality and reliability of ChatGPT and Perplexity′s responses about rectal cancer

YAZICI O., BİR YÜCEL K., Sutcuoglu O.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023

Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients

Uzundal D., YAZICI O., ULAŞ KAHYA B., ÜNER A., ÖZET A., ÖZDEMİR N.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023

The ability of the LACE index to predict 30-day readmissions in oncology patients

ULAŞ KAHYA B., YAZICI O., Sutcuoglu O., ÖZDEMİR N., Gunel N., ÜNER A., et al.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023

HEPATOSELÜLER KANSER TANILI HASTALARDA GRIM SKORUNUN PROGNOSTIK ÖNEMI

Ercan Uzundal D., Yazıcı O., Üner A., Özet A., Özdemir N.

10.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 26 - 30 April 2023, pp.86-87

SISTEMIK ANTI-KANSER TEDAVISINDEN SONRA 30 GÜNLÜK ÖLÜM ORANI, TEK MERKEZ RETROSPEKTIF ANALIZI

ÇETİN T. E., SÜTCÜOĞLU O., ÜNER A., GÜNEL N., SAVAŞ G., ÖZET A., et al.

10. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 26 - 30 April 2023

Moleküler Değerlendirme ile Oligodendroglioma Tanısı Alan Hastalarda Farklı Adjuvan Tedavi Seçeneklerinin Etkinliğinin Değerlendirilmesi

SÜTCÜOĞLU O., İNAN M. A., AKDOĞAN O., ÖZDEMİR N., YAZICI O.

10. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 26 - 30 April 2023

LOKAL İLERİ REKTUM KANSER TANILI HASTALARDA İMMÜNSKOR CD73 EKSPRESYONU VE 53BP1 EKSPRESYONUNUN NEOADJUVAN KEMORADYOTERAPİ ETKİNLİĞİ İLE İLİŞKİSİ

SÜTCÜOĞLU O., İNAN M. A., ÜNER A., SAVAŞ G., BORA H., ÖZET A., et al.

III. Ankara Hematoloji ve Onkoloji Günleri, Ankara, Turkey, 3 - 05 February 2023

Küçük Hücreli Dışı Akciğer Kanseri; Hasta Konseyi

ÜNSAL O., ÇELİK A., TOPKAN E., YAZICI O.

5. Akciğer Kanserinde Güncel Gelişmeler Sempozyumu, Adana, Turkey, 14 January 2023

Hypophysitis associated with immune check point inhibitors : 4 cases, 4 different clinical presentations

Barlas T., Sütçüoğlu O., Yazıcı O., Eroğlu Altınova A.

17. Hipofiz Sempozyumu , Ankara, Turkey, 4 November - 05 December 2022, pp.21-22

EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

YAZICI O., GÜRLER F., ACAR R., GÜRBÜZ M., GÜVEN D. C., BAŞOĞLU TÜYLÜ T., et al.

2022 World Conference on Lung Cancer, 06 August 2022 Sustainable Development

Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

YAZICI O., GÜRLER F., ACAR R., GÜRBÜZ M., GÜVEN D. C., BAŞOĞLU TÜYLÜ T., et al.

2022 World Conference on Lung Cancer, Viyena, Austria, 06 August 2022

Metastatık Renal Hucrelı Karsınom Hastalarında Sıralı Tedavıde Sağkalım, Toksısıte Ve Malıyet Analızı

TURHAN O., SÜTCÜOĞLU O., GÜRLER F., YAZICI O., ÖZDEMİR N., ÖZET A.

9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 May 2022

KANSER VE BESLENME HAKKINDAKİ YOUTUBE VİDEOLARININ BİLİMSEL GÜVENİLİRLİĞİ VE POPÜLARİTESİNİN ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ

Sütcüoğlu O., Özay Z. İ., Özet A., Yazıcı O., Özdemir N.

9.tıbbi onkoloji kongresi, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.59 Sustainable Development

BAŞ VE BOYUN KANSERLERINDE (KEMO) RADYOTERAPI SONRASI PRIMER VE REKÜRREN/ REFRAKTER DOKUDA PD-L1 VE VISTA EKSPRESYON DURUMUNUN KARŞILAŞTIRILMASI

YAZICI ŞENER G., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.

9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 May 2022 Sustainable Development

Erken Evre Mide Kanserinde Cerrahi İle Adjuvan Kemoterapi Arasında Geçen Sürenin Prognoza Etkisi

Bir Yücel K., Sütcüoğlu O., Özdemir N., Yazıcı O.

3. Eskisehir Onkoloji Gunler,, Eskişehir, Turkey, 11 - 13 March 2022, vol.1, no.18, pp.146 Sustainable Development

PDL-1 Testi Yapılan Küçük Hücreli Dışı Akciğer Kanserlilerin (Khdak) Çok Merkezli Türkiye Gerçek Yaşam Klinik Sonuçları

YAZICI O., GÜRLER F., ACAR R., GÜRBÜZ M., GÜVEN D. C., BAŞOĞLU TÜYLÜ T., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

Tam Kan Sayımı Parametreleri İle İleri Evre Mide Kanserli Hastaların Prognozunu Tahmin Edebilir Mi?

Sütcüoğlu O., Fincan A., Gürler F., Kurt İnci B., Özdemir N., Yazıcı O.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

EVRE III KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERLERİNDE NEOADJUVAN KEMOTERAPİ/KEMORADYOTERAPİNİN TÜMÖR DOKUSUNDA PD-L1 VE VİSTA EKSPRESYON DÜZEYİNE ETKİSİ

Akdoğan O., Sütcüoğlu O., Öğüt B., Akyürek N., Özdemir N., Özet A., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 4 - 06 November 2021 Sustainable Development

BEYİN MAGNETİK REZONANS GÖRÜNTÜLEMEDE TEMPORAL KAS ALANI ÖLÇÜMÜNÜN GLİOBLASTOME MULTİFORME PROGNOZU İLE İLİŞKİSİ

Sütcüoğlu O., Akdoğan O., Erdal Z. S., Özdemir N., Özet A., Uçar M., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 04 November 2021

SİSTEMİK ANTİ-HER2 TEDAVİSİ BÜYÜK EKLEM OSTEONEKROZLARINDAN SORUMLU OLABİLİR Mİ?

Altınbezer A., Sütcüoğlu O., Ataoğlu M. B., Yazıcı O.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

KASTRASYONA DİRENÇLİ PROSTAT KANSERİNDE VÜCUT KİTLE İNDEKSİNİN YENİ ANTİ-ANDROJEN TEDAVİLERİNİN TEDAVİ SONUÇLARINA ETKİSİ

Sütcüoğlu O., Yazıcı O., Özdemir N., Üner A., Özet A.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021 Sustainable Development

SARKOPENİ VE OBEZİTENİN METASTATİK RCC HASTALARINDA İMMÜNOTERAPİ TEDAVİSİNİN ETKİNLİĞİNİ ÖNGÖRMEDEKİ ROLÜ,

Aslan V., Sütcüoğlu O., Ünsal O., Yazıcı O., Özdemir N., Üner A., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

İNVAZİV DUKTAL MEME KARSİNOMUNUN PANKREAS METASTAZI: OLAĞANDIŞI TANISAL TUZAKLARI OLAN BİR OLGU

Küçükoğlu Z., Esendağlı G., Sütcüoğlu O., Şimşek B., Yazıcı O.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

ON BİR YIL SONRA TEŞHİS EDİLEN SPONTAN REGRESE OLMUŞ GERM HÜCRELİ TÜMÖR OLGUSU

AYDEMİR E., SÜTCÜOĞLU O., IŞIK GÖNÜL İ., ONARAN M., YAZICI O.

8. Türk Tıbbi Onkoloji Kongresi, Turkey, 03 November 2021

EVRE III KOLOREKTAL KANSERLERDE LENF NODU POZİTİFLİK ORANININ PROGNOSTİK ÖNEMİ

Erdoğan K., Yılmaz N., Sütcüoğlu O., Yazıcı O., Erdoğan A., Özdemir N.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021 Sustainable Development

TIBBİ ONKOLOJI SERVİS YATIŞ SÜRESİNİ ÖNGÖRMEDE HEMOGLOBİN, ALBÜMİN, LENFOSİT VE TROMBOSİT KOMBİNASYONUNUN DEĞERİ

Sütcüoğlu O., Ünsal O., Aslan V., Ulaş Kahya B., Tahtacı G., Özdemir N., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

ALFA-FETOPROTEİN ÜRETEN PRİMER AKCİĞER ADENOKARSİNOM OLGUSU

Ercan Uzundal D., Sütcüoğlu O., Yazıcı O., Özdemir N.

8. Türk Tıbbi Onkoloji Kongresi, 03 November 2021

“The Value of Hemoglobin, Albumin, Lymphocyte and Thrombocyte Combination in Predicting Length Of Stay in the Oncology Service”

Sütcüoğlu O., Özdemir N., Özet A., Yazıcı O.

MEDICRES | 2021 8TH INTERNATIONAL MULTIDISCIPLINARY CONGRESS ON GOOD MEDICAL RESEARCH CONFERENCE, 25 - 28 October 2021

İMMÜNOTERAPİ SONRASI İLK 30 GÜNLÜK MORTALİTE ORANI

Sütcüoğlu O., Ilhan A., Tacar S. Y., Güven D. C., Uçar G., Karadurmuş N., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 03 November 2021

Retrospective Analysis of Co inhibitor and Co stimulator Immune Pathways in Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)

Gürler F., Aktürk Esen S., Kurt İnci B., Sütcüoğlu O., Uçar G., Uncu D., et al.

ESmo Virtual Congress 21, 16 September 2021

Comparison of PD L1 and VISTA Expression Levels in Head and Neck Cancers in Primary and Recurrent Tumor Tissue after Radiotherapy / Chemoradiotherapy

Yazıcı Şener G., Sütcüoğlu O., Öğüt B., Güven D. C., Kavuncuoğlu A., Özdemir N., et al.

ESmo Virtual Congress 21, 16 September 2021 Sustainable Development

Analysis For The False Positive Diagnosis Of PET-CT Scan Due To Surgicel® (Oxidized Regenerated Cellulose) In Operated Lung Cancer Patients

SAYAN M., ŞATIR M., ÖZKAN KOYUNCUOĞLU N. D., AKARSU I., YAZICI O., YILMAZ DEMİRCİ N., et al.

29th Meeting of the European Society of Thoracic Surgeons Virtual Meeting, 20 - 23 June 2021

Analysis For The False Positive Diagnosis Of PET-CT Scan Due To Surgicel® (Oxidized Regenerated CelluPatients

SAYAN M., ŞATIR TÜRK M., ÖZKAN KOYUNCUOĞLU N. D., AKARSU I., YAZICI O., YILMAZ DEMİRCİ N., et al.

29th Meeting of the European Society of Thoracic Surgeons 20 - 22 June 2021, 20 June 2021

FLOT Regımen In Patıents Wıth Metastatıc Gastrıc Adenokarsınoma As Fırst-Lıne Treatment: A Sıngle Center Experıence

GÜRLER F., ÖZET A., ÖZDEMİR N., YAZICI O.

10th International Gastrointestinal Cancers Conference, Ankara, Turkey, 02 December 2020

Survival Expression and corelation analysis of stomach, colon and rectum for survivin

YAZICI O., AKTAŞ S. H., BALI D. F.

10th International Gastrointestinal Cancers Virtual Conference (IGICC 2020), Turkey, 2 - 05 December 2020, pp.33-34

RETROSPECTIVE ANALYSIS OF SORAFENIBTREATMENT IN ADVANCED-STAGEHEPATOCELLULAR CARCINOMA: A SINGLECENTER EXPERIENCE

ÜNSAL O., ASLAN V., YAZICI O., ÜNER A., ÖZET A., ÖZDEMİR N.

10.IGICC, 02 December 2020 - 06 December 2002

THE EFFECT OF THE TIME FROM THE DATE OFPATHOLOGICAL DIAGNOSIS TO THE STARTOF CHEMOTHERAPY IN GASTRIC CANCERPROGNOSIS

SÜTCÜOĞLU O., YAZICI O., ÖZET A., ÖZDEMİR N.

10. IGICC, 2 - 06 December 2020 Sustainable Development

Yeni Bir Tedavi Modeli: İleri Evre Akciğer Adenokarsinomlu Bir Olguda Nivolumab Tedavisinin Aralıklı Kullanımı

ÜNSAL O., ASLAN V., RÜSTEMOVA N., SÜTCÜOĞLU O., KURT İNCİ B., GÜRLER F., et al.

TTOD Sanal Kongresi, Antalya, Turkey, 12 November 2020

Yumuşak Doku Ve Kemik Sarkomlarında Albumin Globulin Oranının Prognostik Rolü

KURT İNCİ B., GÜRLER F., SÜTCÜOĞLU O., ÖZET A., ÖZDEMİR N., YAZICI O.

TTOD Sanal Kongresi, Antalya, Turkey, 12 November 2020

Nötropenik ateş ile başvuran hastada güncel risk indeksleri yeterli mi?

SÜTCÜOĞLU O., AKDOĞAN O., GÜRLER F., KURT İNCİ B., ÖZDEMİR N., YAZICI O.

TTOD Sanal Kongresi, Antalya, Turkey, 12 November 2020

Paraneoplastik Polinöropati Kliniği İle Başvuran Extragonadal Germ Hücreli Tümör Olgusu

ASLAN V., ÜNSAL O., RÜSTEMOVA N., SÜTCÜOĞLU O., ÖZET A., KURT İNCİ B., et al.

TTOD Sanal Kongresi, Antalya, Turkey, 12 November 2020

NÖTROPENİK ATEŞ İLEBAŞVURAN HASTADAGÜNCEL RİSK İNDEKSLERİYETERLİ Mİ?

SÜTCÜOĞLU O., AKDOĞAN O., GÜRLER F., KURT İNCİ B., ÖZDEMİR N., YAZICI O.

TTOD Sanal Kongresi, Turkey, 12 - 15 November 2020

Metastatik Şeffaf Hücreli Renal Karsinom Hastalarında IFN Tedavi Süresi İle Post-IFN Sunitinib Yanıtı İlişkisi

GÜRLER F., KURT İNCİ B., SÜTCÜOĞLU O., YAZICI O., ÖZDEMİR N., ÖZET A.

4. Ulusal İmmünoterapi ve Onkoloji Kongresi, Turkey, 29 October 2020

PARANEOPLASTİK POLİNÖROPATİ KLİNİĞİ İLEBAŞVURAN EXTRAGONADAL GERM HÜCRELİ TÜMÖROLGUSU.

ASLAN V., ÜNSAL O., RUSTEMOVA N., SÜTCÜOĞLU O., KURT İNCİ B., GÜRLER F., et al.

TTOD SANAL KONGRESİ, Turkey, 12 - 15 November 2020

YENİ BİR TEDAVİ MODELİ: İLERİ EVRE AKCİĞERADENOKARSİNOMLU BİR OLGUDA NİVOLUMABTEDAVİSİNİN ARALIKLI KULLANIMI

ÜNSAL O., ASLAN V., RÜSTEMOVA N., SÜTCÜOĞLU O., KURT İNCİ B., GÜRLER F., et al.

TTOD SANAL KONGRESİ, Turkey, 12 - 15 November 2020

Comparıng The Effıcıency Of Interval Debulkıng Surgery After Neoadjuvant Chemotherapy Wıth Prımary Debulkıng Surgery In Patıents Wıth Stage 3 And 4 Ovarıan Carcınoma: Multıcenter Real World Data

YILMAZ M., BAŞAK M., SUNAR V., GÜRLER F., TATAROĞLU ÖZYÜKSELER D., KURT İNCİ B., et al.

European Gynaecological Oncology Congress 2019, Atina, Greece, 05 November 2019

ADJUVAN KEMOTERAPİ SONRASI YALANCI PET POZİTİFLİĞİNİN NEDENLERİNDEN BİRİ KANAMA DURDURUCULAR

ÇELİK A., SAYAN M., BAŞ A., TURK M. Ş., YAZICI O., KURUL İ. C., et al.

TÜRK TORAKS DERNEĞİ TORASİK ONKOLOJİ SEMPOZYUMU, Turkey, 2 - 03 November 2019

KANSER VAKALARINDA BESLENME VE YAŞAM ALIŞKANLIKLARI: 1466 OLGUDA TÜRKIYE PROFILI? OBEZ, TURŞUCU, TELEVIZYONCU VE OTURUCU MUYUZ? TOG PREVANSIYON GRUBU ARAŞTIRMASI

ESİN E., PAYDAŞ S., AKIN TELLI T., ARAZ M., Ilhan A., ALAN Ö., et al.

23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019 Sustainable Development

Primeri Bilinmeyen, Alfa-Fetoprotein (afp) Salgılayan Az Diferansiye Adeno Karsinom: Olgu Sunumu

KURT İNCİ B., GÜRLER F., YAZICI O., ÜNER A.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 April 2019

INI-1 Eksik Malign mezenkimal tümör: Olgu Sunumu

GÜRLER F., KURT İNCİ B., YAZICI O., ÖZET A.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 April 2019

Metastatik Prostat Kanserli (Mpk) Hastalarda 68Ga-Psma-Pet Metabolik Tümör Volumü(Mtv)’Nün ve Maximum Standardize Uptake Değeri (Suvmax)’Nin Prognostik Rolü

KURT İNCİ B., AYDOS U., GÜRLER F., AKDEMİR Ü. Ö., BİR YÜCEL K., GÜLBAHAR ATEŞ S., et al.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 April 2019

Evre 3 ve 4 Over Karsınomlu Hastalarda Neoadjuvan Kemoterapı Sonrası İnterval Debulkıng Cerrahı Etkınlığının Prımer Debulkıng Cerrahı Etkınlığı Ile Karşılaştırılması: Çok Merkezlı Gerçek Yaşam Verılerı.

YILMAZ M., BAŞAK M., SUNAR V., KURT İNCİ B., GÜRLER F., BİR YÜCEL K., et al.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 April 2019

EVRE 3 VE 4 OVER KARSINOMLU HASTALARDA NEOADJUVAN KEMOTERAPI SONRASI İNTERVAL DEBULKING CERRAHI ETKINLIĞININ PRIMER DEBULKING CERRAHI ETKINLIĞI ILE KARŞILAŞTIRILMASI: ÇOK MERKEZLI GERÇEK YAŞAM VERILERI

YILMAZ M., BAŞAK M., SUNAR V., KURT İNCİ B., GÜRLER F., BİR YÜCEL K., et al.

23. ULUSAL KANSER KONGRESİ - 2019, Antalya, Turkey, 17 - 21 April 2019

Kanser Vakalarında Beslenme ve Yaşam Alışkanlıkları: 1466 Olguda Türkiye Profili?Obez, Turşucu, Televizyoncu ve Oturucu muyuz? TOG PREVANSIYON GRUBU ARAŞTIRMASI

ESİN E., PAYDAŞ S., TELLİ T. A., ARAZ M., İLHAN A., ALAN Ö., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019 Sustainable Development

The Importance of Primary TumorLocalization in Locally Advanced GastricCancer with Neoadjuvant Chemotherapy

uçar g., eren t., Ergün Y., YAZICI O., UNCU D., özdemir m., et al.

8 th International Gastrointestinal Cancer Conference, 7 - 09 December 2018

Risk Factors Associated with Relapse in Non-OperativelyMetastatic Renal Cell Carcinoma

uçar g., ERGÜN Y., açıkgöz y., YAZICI O., ÖZDEMİR N., UNCU D.

2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Turkey, 30 October - 04 November 2018, pp.35

ileri evre kolorektal kanserde RAS mutasyon durumu ve tümör lokalizasyonunun PET-BT 18F-FDG tutulumu ile ilişkisi

KURT İNCİ B., gürler F., YILMAZ M., TAHTACI G., YAZICI O., ÜNER A., et al.

2. ulusal immunoterapi ve onkoloji kongresi, Turkey, 31 October - 04 November 2018 Sustainable Development

The effectt of sarcopenia on acute chemotherapy toxicity in gasrtointestinal cancer patients undergoing systemic therapy

ÖZDEMİR N., YAZICI O., SILAY K., uçar g., eren t., ŞENER DEDE D., et al.

esmo 2018, 19 - 23 October 2018 Sustainable Development

Current Status of Metastatic Colorectal Cancer in East Europe and Middle East

YAZICI O., uçar g., Vamvakopoulou V., turhal S., Yıldız B., Karamouzis M., et al.

2 nd International Congress on Oncological Sicences, 20 - 23 September 2018 Sustainable Development

Take home messages-Medical Oncology -I

YAZICI O.

8.th Eurasian Uro-Oncology Congress, 28 June - 01 July 2018

Baş Boyun Karsinomlu 70 Yaş Ve Üzeri Hastalarda Adjuvan Yaklaşım: TOG Baş Boyun Kanserleri Grubu Çalışması

METCALFE E., YAZICI O., KORKMAZ KIRAKLI E., ALTINOK A., ARSLAN AYTAÇ S., IBRAHIMOV R., et al.

13. Ulusal Radyasyon Onkolojisi Kongresi, Lefkoşa, Cyprus (Kktc), 27 April - 01 May 2018, pp.33 Sustainable Development

Nadir görülen bir olgu: Çekum yerleşimli soliter plasmositom

eren t., ÖZDEMİR N., UNCU D., YAZICI O., uçar g., ERGÜN Y., et al.

7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018, pp.320

Gebelik sırasında tespit edilen hormon pozitif nadir bir tümör: Agresif anjiyomiksoma

eren t., YAZICI O., uçar g., ERGÜN Y., UNCU D., ZENGİN N.

7. Türk Tıbbi Onkoloji Kongresi, Turkey, 21 - 25 March 2018, pp.303

TESTİS LENFOMALI HASTADA GELİŞEN SERVİKAL SPİNAL RADYONEKROZUN BEVACİZUMAB İLE TEDAVİSİ

EREN T., ÖZDEMİR N., YAZICI O., UNCU D., BAL Ö., ALGIN E., et al.

7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018

NADİR GÖRÜLEN BİR OLGU: ÇEKUM YERLEŞİMLİ SOLİTER plasmAsİtom

EREN T., ÖZDEMİR N., UNCU D., YAZICI O., UÇAR G., ERGÜN Y., et al.

7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018

LENF NODU NEGATİF ERKEN EVRE MİDE KANSERİNDE TÜMÖR ÇAPI: PROGNOSTİK MİDİR?

ÖZDEMİR N., KOCABAŞ M., ASLAN S., YAZICI O., ŞENDUR M. A. N., SILAY K., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017 Sustainable Development

MEME KANSERİ TANISI ALAN DİYABETİK HASTALARDA KULLANILAN ANTİDİYABETİK TEDAVİNİN KLİNİKOPATOLOJİK ÖZELLİKLER VE SAĞKALIM ÜZERİNE ETKİSİNİN İNCELENMESİ

ŞENDUR M. A. N., AKSOY S., BİLGİN B., YAZICI O., YILDIRIM ÖZDEMİR N., ŞENER DEDE D., et al.

6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016 Sustainable Development

2015 YILI TÜRKİYE KAYNAKLI ONKOLOJİK YAYINLARIN TÜM YAYINLAR İÇİNDEKİ YERİ VE ÖNEMİ

ŞENDUR M. A. N., BİLGİN B., YAZICI O., AKSOY S., YILDIRIM ÖZDEMİR N., AKINCI M. B., et al.

6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016

The efficacy and predictive factors of response of second line triplet modified EOX epirubicin oxaliplatin capacitabine regimen in metastatic gastric cancer

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015 Sustainable Development

TheEffect of International Prognostic Index IPI in the Determination of Prognosis of Early Stage Diffuse Large B Cell Non Hodgkin Lymphoma Is it Enough

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015

The importance of thiol disulphide homeostasis in patients with advanced gastric cancer AGC receiving modified docetaxel and cisplatin plus fluorouracil mDCF regimen

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015 Sustainable Development

Study of the impact of Charlson comorbidity index on the efficacy of adjuvant trastuzumab in patients with HER2 positive early breast cancer

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015 Sustainable Development

The Comparison of Early Stage Primary Nodal and Extranodal Diffuse Large Cell Lymphomas Clinical Features Treatment and Survival Outcomes

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015

The importance of thiol disulphide homeostasis in patients with advanced colorectal cancer receiving modified fluorouracil and leucoverin plus oxaliplatin mFOLFOX regimen

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015 Sustainable Development

Operated and Early Stage Ampulla Vateri Tumours Prognostic Assessment

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015

Effect of regular exercise on survival in women with early stage luminal a breast cancer

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

18th ECCO-40th ESMO Congress, 25 - 29 September 2015 Sustainable Development

Kutanöz Büyük B Hücreli Lenfoma Tanılı Hastada Relaps Sonrası Gemsitabin Oxaliplatin Deneyimi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015

Malignite Potansiyeli Yüksek Böbrek Anjiomiyolipomu Epiteloid Varyant

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015

Non Metastatik Kolorektal Kanser Tanılı Hastalarda Tanı Anındaki Tiroid Stimülan Hormon Seviyesinin Önemi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Kolon Kanserli Hastada Çoklu Metastzektomi Deneyimi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Non Metastatik Kolorektal Kanserli Hastalarda Çıkarılan Negatif Lenf Nodlarının Toplam Ve Hastalıksız Sağkalım Üzerine Etkisi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Lipid Profili Ve Kolon Kanseri İlişkisi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Evre II Rektum Kanserli Hastalarda Oxaliplatin Tedavisinin Sağkalım Verileri Üzerine Etkisi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Mide Kanserli Hastalarda Semptomatik Ve Asemptomatik Tromboembolizm in Değerlendirilmesi

Doğan M., Güven Z. T., Uncu D., Algın E., Bal Ö., YAZICI O., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, Turkey, 17 - 19 September 2015 Sustainable Development

Brain specific progression free survival bsPFS according to breast cancer subtypes in patients with brain metastases

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

2015 ASCO Annual Meeting, 29 May - 02 June 2015 Sustainable Development

Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancer

YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Akinci M. B., ZENGİN N., et al.

2015 ASCO Annual Meeting, 29 May - 02 June 2015 Sustainable Development

The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)

Yazici O., Ozdemir N., Duran A. O., Menekse S., Sendur M. A. N., Karaca H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33 Sustainable Development